Open AccessComparative Cardiovascular Risk of Abatacept and Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis With and Without Diabetes Mellitus: A Multidatabase Cohort Study
Author(s) -
Kang Eun Ha,
Jin Yinzhu,
Brill Gregory,
Lewey Jennifer,
Patorno Elisabetta,
Desai Rishi J.,
Kim Seoyoung C.
Publication year - 2018
Publication title -
journal of the american heart association
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.494
H-Index - 85
ISSN - 2047-9980
DOI - 10.1161/jaha.117.007393
Subject(s) - abatacept , medicine , rheumatoid arthritis , hazard ratio , tnf inhibitor , cohort , diabetes mellitus , myocardial infarction , proportional hazards model , confidence interval , odds ratio , etanercept , endocrinology , rituximab , lymphoma
Background We examined the cardiovascular risk of abatacept compared with tumor necrosis factor ( TNF ) inhibitors in patients with rheumatoid arthritis with and without diabetes mellitus ( DM ). Methods and Results We conducted a cohort study of patients with rheumatoid arthritis who newly started abatacept or TNF inhibitors using claims data from Medicare and MarketScan. The primary outcome was a composite cardiovascular end point of myocardial infarction ( MI ), stroke/transient ischemic attack, and coronary revascularization. To account for >60 baseline characteristics, abatacept initiators were 1:1 propensity score ( PS ) matched to TNF initiators in each database. Cox proportional hazards models estimated hazard ratio ( HR ) and 95% confidence interval ( CI ) in the PS ‐matched cohort per database. A fixed‐effects meta‐analysis pooled database‐specific HR s. We included a total of 13 039 PS ‐matched pairs of abatacept and TNF inhibitor initiators (6103 pairs in Medicare and 6936 pairs in MarketScan). A total of 34.7% in Medicare and 19.8% in MarketScan had baseline DM . The HR (95% CI ) for the primary outcome associated with abatacept use versus TNF inhibitor was 0.81 (0.66–0.99) in Medicare and 0.95 (0.74–1.23) in MarketScan, with a pooled HR of 0.86 (95% CI, 0.73–1.01; P =0.3 for heterogeneity). The risk of the primary outcome was lower in abatacept initiators versus TNF inhibitors in the DM subgroup, with a pooled HR of 0.74 (95% CI, 0.57–0.96; P =0.7 for heterogeneity), but not in the non‐ DM subgroup, with a pooled HR of 0.94 (95% CI, 0.77–1.14; P =0.4 for heterogeneity). Conclusions In this large population‐based cohort of patients with rheumatoid arthritis, abatacept use appeared to be associated with a modestly reduced cardiovascular risk when compared with TNF inhibitor use, particularly in patients with DM.